Isotretinoin systemic therapy and the shadow cast upon dermatology's downtrodden hero

Clinics in Dermatology

Volumn 29, Issue 6, 2011, Pages 652-661

  Lowenstein, Elie B ^a   Lowenstein, Eve J ^b,c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b BROOKDALE UNIVERSITY HOSPITAL AND MEDICAL CENTER   (United States)

^c SUNY Downstate Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMINOTRANSFERASE; ETRETIN; GEMFIBROZIL; HYPERICUM PERFORATUM EXTRACT; ISOTRETINOIN; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; PHENYTOIN; PROGESTERONE; RETINOID; RETINOL; TETRACYCLINE; THALIDOMIDE; TRIACYLGLYCEROL; WARFARIN;

BLEPHAROCONJUNCTIVITIS; BRAIN FUNCTION; BRAIN PSEUDOTUMOR; CHEILITIS; CLINICAL FEATURE; COLOR VISION; CONFUSION; CONJUNCTIVITIS; CORNEA OPACITY; CROHN DISEASE; DEPRESSION; DISEASE ASSOCIATION; DIZZINESS; DRUG BIOAVAILABILITY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; EYE IRRITATION; FATIGUE; HEADACHE; HIGH RISK PATIENT; HUMAN; HYDROCEPHALUS; HYPEROSTOSIS; HYPERTRIGLYCERIDEMIA; INSOMNIA; INTRACRANIAL PRESSURE; KERATINIZATION; KERATITIS; LETHARGY; LIVER FUNCTION TEST; LONG TERM CARE; MALAISE; MICROCEPHALY; MICROPHTHALMIA; MYOPIA; NEPHROTOXICITY; NIGHT BLINDNESS; NONHUMAN; NOTE; OSTEOMALACIA; PATIENT COMPLIANCE; PATIENT MONITORING; PHOTOPHOBIA; PREGNANCY; PRIORITY JOURNAL; QUALITY OF LIFE; RADIOSENSITIVITY; RISK FACTOR; SEIZURE; SIDE EFFECT; SPERMATOZOON COUNT; SPONTANEOUS ABORTION; STROKE; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; SYNCOPE; SYSTEMIC THERAPY; TERATOGENICITY; TRIACYLGLYCEROL BLOOD LEVEL; ULCERATIVE COLITIS; WEAKNESS; XEROSTOMIA;

ACNE VULGARIS; DERMATOLOGIC AGENTS; DRUG APPROVAL; FACIAL DERMATOSES; HUMANS; HYPOPIGMENTATION; ISOTRETINOIN; KELOID; TONGUE DISEASES; UNITED STATES;

EID: 80054764516     PISSN: 0738081X     EISSN: 18791131     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2011.08.026     Document Type: Note

References (167)

1. Szasz T. The Second Sin 1973, 115. Doubleday Anchor, New York.
2. Ellis C., Krach K. Uses and complications of isotretinoin therapy. J Am Acad Dermatol 2001, 45:S150-S157.
3. Moshell A.N. Skin cancer chemoprevention with systemic retinoids: an adjunct in the management of selected high-risk patients. Cutis 1989, 43:485-490.
4. Campbell R.M., DiGiovanna J.J. Retinoid chemoprevention in the high-risk patient. Dermatol Ther 2006, 19:306-314.
5. Palestine AG: Transient acute myopia resulting from isotretinoin (Accutane) therapy. Ann Ophthalmol. 1984; 16:660,662.
6. Blaner W.S., Olson J.A. Retinol and retinoic acid metabolism. The retinoids, biology, chemistry, and medicine 1994, 229-255. Raven Press, New York. M.B. Sporn, A.B. Roberts, D.S. Goodman (Eds.).
7. Tang G., Russell R.M. Formation of all-trans-retinoic acid and 13-cis-retinoic acid from all-trans-retinyl palmitate in humans. J Nutr Biochem 1991, 2:2100-2213.
8. Goulden V., Layton A.M., Cunliffe W.J. Long-term safety of isotretinoin as a treatment for acne vulgaris. Br J Dermatol 1994, 131:360-363.
9. Layton A.M., Knaggs H., Taylor J., et al. Isotretinoin for acne vulgaris-ten years later: a safe and successful treatment. Br J Dermatol 1993, 129:292-296.
10. WJ Cunliffe P.C.M., van de Kerhof R., Caputo S., et al. Roaccutane Treatment Guidelines: Results of an International Survey. Dermatology 1997, 194:351-357.
11. Hanson N., Leachman S. Safety issues in isotretinoin therapy. Semin Cutan Med Surg 2001, 20:166-183.
12. Mitchell A.A., Van Bennekom C.M., Louik C. A pregnancy-prevention program in women of childbearing age receiving isotretinoin. N Engl J Med 1995, 333:101-106.
13. Lammer E.J., Chen D.T., Hoar R.M., et al. Retinoic acid embryopathy. N Engl J Med 1985, 313:837-841.
14. Rosa F.W., Wilk A.L., Kelsey F.O. Teratogen update: Vitamin A congeners. Teratology 1986, 33:355-364.
15. Goldfarb M.T., Ellis C.N. The uses of retinoids in dermatology. Curr Opin Dermatol 1997, 4:236-240.
16. DiGiovanna J.J. Systemic Retinoid Therapy. Dermatol Clin 2001, 19:161-167.
17. PDR Staff Isotretinoin. Physicians' Desk Reference 1999, 2651-2653. Medical Economics Co, New Jersey. PDR Staff (Ed.).
18. Rizzo R., Lammer E.J., Parano E., et al. Limb reduction defects in humans associated with prenatal isotretinoin exposure. Teratology 1991, 44:599-604.
19. Meadows M. The Power of Accutane: The Benefits and Risks of a Breakthrough Acne Drug. FDA Consumer 2001, 35:18-23.
20. Lowenstein E.J. Isotretinoin Made S.M.A.R.T. and Simple. Cutis 2002, 70:115-120.
21. McLane J. Analysis of Common Side Effects of Isotretinoin. J Am Acad Dermatol 2001, 45:S188-S194.
22. Lindemayr H. Isotretinoin intoxication in attempted suicide. Acta Derm Venereol 1986, 66:452-453.
23. Duke E., Guenther L. Psychiatric reactions to the retinoids. Can J Dermatol 1992, 5:467.
24. Byrne A., Costello M., Greene E., et al. Isotretinoin therapy and depression: evidence for an association. Ir J Psychol Med 1998, 15:58-60.
25. Hazen P.G., Carney J.F., Walker A.E., et al. Depression-a side effect of 13-cis-retinoic acid therapy. J Am Acad Dermatol 1983, 9:278-279.
26. Scheinman P.L., Peck G.L., Rubinow D.R., et al. Acute depression from isotretinoin. J Am Acad Dermatol 1990, 22:1112-1114.
27. Byrne A., Hnatko G. Depression associated with isotretinoin therapy. Can J Psychiatry 1995, 40:567.
28. Bruno N.P., Beacham B.E., Burnett J.W. Adverse Effects of isotretinoin therapy. Cutis 1984, 33:484-489.
29. Bachmann C., Grabarkiewicz J., Theisen F.M., et al. Isotretinoin, depression and suicide ideation in an adolescent boy. Pharmacopsychiatry 2007, 40:128.
30. Wysowski D.K., Pitts M., Beitz J. An analysis of reports of depression and suicide in patients treated with isotretinoin. J Am Acad Dermatol 2001, 45:515-519.
31. Zetterstrom R.H., Simon A., Giacobini M.M.J., et al. Localization of cellular retinoid-binding proteins suggest specific roles for retinoids in the adult central nervous system. Neuroscience 1994, 62:899-918.
32. Krezel W., Ghyselinck N., Samad T.A., et al. Impaired locomotion and dopamine signaling in retinoid receptor mutant mice. Science 1998, 279:863-867.
33. Chiang M.Y., Misner D., Kempermann G., et al. An essential role for retinoid receptors RAR beta and RXR gamma in long-term potentiation and depression. Neuron 1998, 21:1353-1361.
34. Samad T.A., Krezel W., Chambon P., et al. Regulation of dopaminergic pathways by retinoids: activation of the D2 receptor promoter by members of the retinoic acid receptorretinoid X receptor family. Proc Natl Acad Sci U S A 1997, 94:14349-14354.
35. McCaffery P., Drager U.C. High levels of a retinoic acid-generating dehydrogenase in the meso-telencephalic dopamine system. Proc Natl Acad Sci U S A 1994, 91:7772-7776.
36. Ferguson S.A., Cisneros F.J., Hanig J.P., et al. Oral treatment with Accutane does not increase measures of anhedonia or depression in rats. Neurotoxicol Teratol 2007, 29:642-651.
37. Ferguson S.A., Cisneros F.J., Gough B., et al. Chronic oral treatment with 13-cis-retinoic acid (isotretinoin) or all-trans-retinoic acid does not alter depression-like behaviors in rats, Toxicol. Sci 2005, 87:451-459.
38. Ferguson S.A., Siitonen P.H., Cisneros F.J., et al. Steady state pharmacokinetics of oral treatment with 13-cis-retinoic acid or all-trans-retinoic acid in male and female adult rats. Basic Clin Pharm Toxicol 2006, 98:582-587.
39. Bremner J.D., Fani N., Ashraf A., et al. Functional brain imaging alterations in acne patients treated with isotretinoin. Am J Psychiatry 2005, 162:983-991.
40. Marqueling A.L., Zane L.T. Depression and suicidal behavior in acne patients treated with isotretinoin: a systematic review. Semin Cutan Med Surg 2007, 26:210-220.
41. Ng C.H., Tam M.M., Celi E., et al. Prospective study of depressive symptoms and quality of life in acne vulgaris patients treated with isotretinoin compared to antibiotic and topical therapy. Australas J Dermatol 2002, 43:262-268.
42. Jacobs D.G., Deutsch N.L., Brewer M. Suicide, depression, and isotretinoin: is there a causal link?. J Am Acad Dermatol 2001, 45:S168-S175.
43. Jick S.S., Kremers H.M., Vasilakis-Scaramozza C. Isotretinoin use and risk of depression, psychotic symptoms, suicide, and attempted suicide. Arch Dermatol 2000, 136:1231-1236.
44. Rubinow D., Peck G., Squillace K., et al. Reduced anxiety and depression in cystic acne patients after successful treatment with oral isotretinoin. J Am Acad Dermatol 1987, 17:25-32.
45. Kellett S., Gawkrodger D. The psychological and emotional impact of acne and the effect of treatment with isotretinoin. Br J Dermatol 1999, 140:273-282.
46. Azoulay L., Blais L., Koren G., et al. Isotretinoin and the risk of depression in patients with acne vulgaris: a case-crossover study. J Clin Psychiatry 2008, 69:526-532.
47. Kaymak Y., Taner E., Taner Y. Comparison of depression, anxiety and life quality in acne vulgaris patients who were treated with either isotretinoin or topical agents. Int J Dermatol 2009, 48:41-46.
48. Rehn L.M., Meririnne E., Höök-Nikanne J., et al. Depressive symptoms and suicidal ideation during isotretinoin treatment: a 12-week follow-up study of male Finnish military conscripts. J Eur Acad Dermatol Venereol 2009, 23:1294-1297.
49. Sundström A., Alfredsson L., Sjölin-Forsberg G., et al. Association of suicide attempts with acne and treatment with isotretinoin: retrospective Swedish cohort study. BMJ 2010, 341:c5812.
50. Magin P., Sullivan J. Suicide attempts in people taking isotretinoin for acne. BMJ 2010, 341:c5866.
51. Cunliffe W. Management of adult acne and acne variants. J Cutan Med Surg 1998, 3:S7-S13.
52. Cotterill J., Cunliffe W. Suicide in dermatologic patients. Br J Dermatol 1997, 137:246-250.
53. Gupta M., Gupta A. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol 1998, 139:846-850.
54. Hull P.R., D'Arcy C. Acne, depression, and suicide. Dermatol Clin 2005, 23:665-674.
55. Hull P.R., D'Arcy C. Isotretinoin use and subsequent depression and suicide: presenting the evidence. Am J Clin Dermatol 2003, 4:493-505.
56. Adams J., Lamer E.J. Neurobehavioral teratology of isotretinoin. Reprod Toxicol 1993, 7:175-177.
57. Fraunfelder F.T., LaBraico J.M., Meyer S.M. Adverse ocular reactions possibly associated with isotretinoin. Am J Ophthalmol 1985, 100:534-537.
58. Maclean H., Wright M., Choi D., et al. Abnormal night vision with isotretinoin therapy for acne. Clin Exp Dermatol 1995, 20:86.
59. Lee A.G. Pseudotumor Cerebri after treatment with tetracycline and isotretinoin for acne. Cutis 1995, 55:165-168.
60. Brown R.D., Grattan C.E. Visual toxicity of synthetic retinoids. Br J Ophthalmol 1989, 73:286-288.
61. Spector R.H., Carlisle J. Pseudotumor cerebri caused by a synthetic vitamin A preparation. Neurology 1984, 34:1509-1511.
62. Ishikawa J., Sutoh C., Ishikawa A., et al. S 13-cis-retinoic acid alters the cellular morphology of slice-cultured serotonergic neurons in the rat. Eur J Neurosci 2008, 27:2363-2372.
63. Sei H. Vitamin A and sleep regulation. J Med Invest 2008, 55:1-8.
64. Smedje H., Schwan S., Hallberg E., et al. Onset of Kleine-Levin Syndrome in association with isotretinoin treatment. Acta Paediatr 2010, 99:946-948.
65. McLane J. Analyis of common side effects of isotretinoin. J Am Acad Dermatol 2001, 45:S188-S194.
66. Ling T.C., Highet A.S. Isotretinoin associated with craving for cigarettes. Br J Dermatol 2000, 142:198-199.
67. Layton A., Hughes B., Hull S., et al. Seborrhea-an indicator for poor clinical response in acne patients treated with antibiotics. Clin Exp Dermatol 1992, 17:173-175.
68. Ellis C.N., Voorhees J.J. Etretinate therapy. J Am Acad Dermatol 1987, 16:267-291.
69. Leyden J.J. The role of isotretinoin in the treatment of acne: personal observations. J Am Acad Dermatol 1998, 39:S45-S49.
70. Peck G.L., DiGiovanna J.J. The retinoids. Fitzpatrick's dermatology in general medicine 1999, 2810-2820. McGraw-Hill, New York. I.M. Freedberg, A.Z. Eisen, K. Wolff (Eds.).
71. Shalita A.R., Cunningham W.J., Leyden J.J., et al. Isotretinoin treatment of acne and related disorders: An Update. J Am Acad Dermatol 1983, 9:629-638.
72. Graham M.L., Corey R., Califf R., et al. Isotretinoin and Staphyloccocus aureus infection: A possible association. Arch Dermatol 1986, 122:815-817.
73. Graham B.S., Barrett T.L. Mucosal denudation of the lips from isotretinoin therapy. Arch Dermatol 1999, 135:349-350.
74. Scheinfeld N., Bangalore S. Facial edema induced by isotretinoin use: a case and a review of the side effects of isotretinoin. J Drugs Dermatol 2006, 5:467-468.
75. Estival J.L., Dupin M., Kanitakis J., et al. Capillary Leak Syndrome Induced by Acitretin. Br J Dermatol 2004, 150:150-152.
76. Meigel W.N. How Safe is Oral Isotretinoin?. Dermatology 1997, 195:22-28.
77. Gendimenico G.J., Mezick J.A. Pharmacological effects of retinoids on skin cells. Skin Pharmacol 1993, 6:24-34.
78. Lupi-Pegurier L., Muller-Bolla M., Fontas E., et al. Reduced salivary flow Induced by systemic Isotretinoin may lead to dental decay. A Prospective Clinical Study. Dermatology 2007, 214:221-226.
79. Oikarinen K., Salo T., Kylmaniemi M., et al. Systemic oral isotretinoin therapy and flow rate, pH, and matrix metalloproteinase-9 activity of stimulated saliva. Acta Odontol Scand 1995, 53:369-371.
80. Daly T.J., Weston W.L. Retinoid effects on fibroblast proliferation and collagen synthesis in vitro and on fibrotic disease in vivo. J Am Acad Dermatol 1986, (4 Pt 2):900-902.
81. Janssen de Limpens A.M. The local treatment of hypertrophic scars and keloids with topical retinoic acid. Br J Dermatol 1980, 103:319-323.
82. Zachariae H. Delayed wound healing and keloid formation following argon laser treatment or dermabrasion during isotretinoin treatment. Br J Dermatol 1988, 118:703-706.
83. Bernestein L.J., Geronemus R.G. Keloid formation with the 585-nm pulsed dye laser during Isotretinoin treatment. Arch Dermatol 1997, 133:111-112.
84. Rubenstein R., Roenigk H.J., Stegman S., et al. Atypical keloids after dermabrasion of patients taking isotretinoin. J Am Acad Dermatol 1986, 15:280-285.
85. Goihman-Yah M. Correspondence. Int J Dermatol 1999, 38:228-229.
86. Manzano R., Herranz P., Borbujo J., et al. Keloid appearance during isotretinoin therapy for acne. Actas Dermosifiliogr 1995, 86:123-126.
87. Ginarte M., Peteiro C., Toribio J. Keloid formation induced by isotretinoin therapy. Int J Dermatol 1999, 38:228-229.
88. Bauer E.A., Seltzer J.L., Eisen A.Z. Inhibition of collagen degradative enzymes by retinoic acid in vitro. J Am Acad Dermatol 1982, 6:603-607.
89. Abergel R.P., Meeker C.A., Helja O., et al. Retinoid Modulation of Connective Tissue Metabolism in Keloid Fibroblast Cultures. Arch Dermatol 1985, 121:632-636.
90. Cruz N.I. Inhibition of human fibroblast growth by Isotretinoin and triamcinolone acetonide in Vitro. Ann Plast Surg 1994, 33:401-405.
91. Ruiz-Maldonado R., Tamayo-Sanchez L., Orozco-Covarrubias M.L. The use of retinoids in the pediatric patient. Dermatol Clin 1998, 16:553-569.
92. Strauss J., Gottlieb A., Jones T., et al. Concomitant administration of vitamin E does not change the side effects of isotretinoin as used in acne vulgaris: a randomized trial. J Am Acad Dermatol 2000, 43:777-784.
93. Salasche S.J., Lebwohl M. Clinical pearl: vitamin E (alpha-tocopherol), 800 IU daily, may reduce retinoid toxicity. J Am Acad Dermatol 1999, 41:260.
94. Besa E., Abrahm J., Bartholomew M., et al. Treatment with 13-cis-retinoic acid in transfusion-dependent patients with myelodysplastic syndrome and decreased toxicity with addition of alpha-tocophorol. Am J Med 1990, 89:739-747.
95. Lebwohl M. Clinical pearl: vitamin E (alpha-tocopherol), 800 IU daily,may reduce retinoid toxicity. J Am Acad Dermatol 1999, 41:260.
96. Fraunfelder F.T., Fraunfelder F.W., Edwards R. Ocular side effects possibly associated with Isotretinoin usage. Am J Ophthalmol 2001, 132:299-305.
97. Lerman S. Ocular side effects of accutane therapy. Lens Eye Toxic Res 1992, 9:429-438.
98. Fisher D.A. Exercise-induced bronchoconstriction related to isotretinoin therapy. J Am Acad Dermatol 1985, 13:524.
99. Kapur N., Hughes J.R., Rustin M.H. Exacerbation of asthma by isotretinoin. Br J Dermatol 2000, 142:388-389.
100. Sabroe R.A., Staughton R.C., Bunker C.B. Bronchospasm induced by isotretinoin. BMJ 1996, 312:886.
101. Korelitz B.I. Systemic 13-cis retinoic acid therapy and exacerbation of colitis. JAMA 1984, 252:2463. [letter].
102. Bernstein C.N., Nugent Z., Longobardi T., et al. Isotretinoin is not associated with inflammatory bowel disease: a population-based case-control study. Am J Gastroenterol 2009, 104:2774-2778.
103. Crockett S., Gulati A., Sandler R.S., et al. A causal association between Accutane and IBD has yet to be established. Am J Gastroenterol 2009, 104:2387-2393.
104. Schleicher S.M. Oral isotretinoin and inflammatory bowel disease. J Am Acad Dermatol 1985, 13:834-835.
105. Godfrey K.M., James M.P. Treatment of severe acne with isotretinoin in patients with inflammatory bowel disease. Int J Dermatol 1990, 123:653-655.
106. Ahmed R., Pezzone M. Isoretinoin-associated ulcerative colitis. Am J Gastroenterol 2006, 101:S394.
107. Bankar R.N., Dafe C.O., Kohnke A., et al. Ulcerative colitis probably associated with isotretinoin. Indian J Gastroenterol 2006, 25:171-172.
108. Borobio E., Arin A., Valcayo A., et al. Isotretinoin and ulcerous colitis. An Sist Sanit Navar 2004, 27:241-243.
109. Mennecier D., Poyet R., Thiolet C., et al. Ulcerative colitis probably induced by isotretinoin. Gastroenterol Clin Biol 2005, 29:1306-1307.
110. Passier J.L., Srivastava N., van Puijenbroek E.P. Isotretinoin-induced inflamatory bowel disease. Neth J Med 2006, 64:52-54.
111. Reniers D.E., Howard J.M. Isotretinoin-induced infl ammatory bowel disease in an adolescent. Ann Pharmacother 2001, 35:1214-1216.
112. Rolanda C., Macedo G. Isotretinoin and inflammatory bowel disease. Am J Gastroenterol 2007, 102:1330.
113. Reddy D., Siegel C.A., Sands B.E., et al. Possible association between isotretinoin and inflammatory bowel disease. Am J Gastroenterol 2006, 101:1569-1573.
114. Martin P., Manley P.N., Depew W.T., et al. Isotretinoin-associated proctosigmoiditis. Gastroenterology 1987, 93:606-609.
115. Spada C., Riccioni M.E., Marchese M., et al. Isotretinoin-associated panenteritis. J Clin Gastroenterol 2008, 42:923-925.
116. Crockett S.D., Porter C.Q., Martin C.F., et al. Isotretinoin use and the risk of inflammatory bowel disease: A Case - Control Study. Am J Gastroenterol 2010, 105:1986-1993.
117. Voreacos D. Roche found liable in first of 400 suits over Accutane; acne drug ruled to cause bowel disease 2007, The Washington Post, May 30.
118. Cunningham B.B. Acne controversies: An update based on recent findings. Practical Dermatology 2010.
119. Sewell J.L., Mahadevan U. Of blemishes and bowels: Isotretinoin and inflammatory bowel disease. Gastroenterology 2010, 138:392-394.
120. DiGiovanna J. Isotretinoin effects on bone. J Am Acad Dermatol 2001, 45:S176-S182.
121. Fiallo P., Tagliapietra A.G. Severe acute myopathy induced by isotretinoin. Arch Dermatol 1996, 132:1521-1522.
122. Roche Laboratories Inc Accutane. PDR Staff: Physicians' Desk Reference 2000, 2610-2612. Medical Economics Co, New Jersey.
123. Pennes D.R., Ellis C.N., Madison K.C., et al. Early skeletal hyperostoses secondary to 13-cis-retinoic-acid. Am J Roentgenol 1984, 142:979-983.
124. Vestergaard P., Rejnmark L., Mosekilde L. High-dose treatment with vitamin A analogues and risk of fractures. Arch Dermatol 2010, 146:478-482.
125. Trauner M.A., Ruben B.S. Isotretinoin induced rhabdomyolysis: A case report. Dermatol Online J 1999, 5:2.
126. Camisa C. Acute arthritis during isotretinoin therapy for acne. J Am Acad Dermatol 1986, 15:1061-1062.
127. Matsuoka L.Y., Wortsman J., Pepper J.J. Acute arthritis during isotretinoin treatment for acne. Arch Intern Med 1984, 144:1870-1871.
128. Barbareschi M., Paresce E., Chiaratti A., et al. Unilateral sacroiliitis associated with systemic isotretinoin treatment. Int J Dermatol 2010, 49:331-333.
129. Eksioglu E., Oztekin F., Unlu E., et al. Sacroiliitis and polyneuropathy during isotretinoin treatment. Clin Exp Dermatol 2008, 33:122-124.
130. Bottomley W.W., Cunliffe W.J. Acute Achilles tendonitis following oral isotretinoin therapy for acne vulgaris. Clin Exp Dermatol 1992, 17:250-251.
131. Aractingi S., Lassoued K., Dubertret L. Post-isotretinoin vasculitis. Lancet 1990, 335:362.
132. Dwyer J.M., Kenicer K., Thompson B.T., et al. Vasculitis and retinoids. Lancet 1989, 2:494-496.
133. Chochrad D., Langhendries J.P., Stolear J.C., et al. Isotretinoin-induced vasculitis imitating polyarteritis nodosa, with perinuclear antineutrophil cytoplasmic antibody in titers correlated with clinical symptoms. Rev Rhum Engl Ed 1997, 64:129-131.
134. Epstein E.H., McNutt N.S., Beallo R., et al. Severe vasculitis during isotretinoin therapy. Arch Dermatol 1987, 123:1123-1125.
135. Friedman S.J. Leukopenia and neutropenia associated with isotretinoin therapy. Arch Dermatol 1987, 123:293-295.
136. Johnson T.M., Rapini R.P. Isotretinoin-induced thrombocytopenia. J Am Acad Dermatol 1987, 17:838-839.
137. Michaelsson G., Vahlquist A., Mobacken H., et al. Changes in laboratory variables induced by isotretinoin treatment of acne. Acta Derm Venereol 1986, 66:144-148.
138. Dootson G.M., Keidan J., Anderson J.A. Exacerbation of bleeding tendency in a patient with haemophilia A during treatment with isotretinoin. Br J Dermatol 1992, 127:186-187.
139. Dootson G.M., Keidan J., Harper P.L. The influence of isotretinoin upon fibrinolysis in patients with acne. Br J Dermatol 1995, 133:66-70.
140. Zane L.T., Leyden W.A., Marqueling A.L., et al. A population-based analysis of laboratory abnormalities during Isotretinoin therapy for acne vulgaris. Arch Dermatol 2006, 142:1016-1022.
141. Shalita A.R. Mucocutaneous and systemic toxicity of retinoids: monitoring and management. Dermatologica 1987, 175:151-157.
142. Strauss J.S., Rapini R.P., Shaltia A.R., et al. Isotretinoin therapy for acne: Results of a multicenter dose-response study. J Am Acad Dermatol 1984, 10:490-496.
143. Lyons F., Laker M.F., Marsden J.R., et al. Effect of oral 13-cis-retinoic acid on serum lipids. Br J Dermatol 1982, 107:591-595.
144. Bershad S., Rubinstein A., Paterniti J.R., et al. Changes in plasma lipids and lipoproteins during isotretinoin therapy for acne. N Engl J Med 1985, 313:981-985.
145. Vahlquist C., Michaelsson G., Vahlquist A., et al. A sequential comparison of etretinate (Tigason) and isotretinoin (Roaccutane) with special regard to their effects on serum lipoproteins. Br J Dermatol 1985, 112:69-76.
146. Marsden J. Hyperlipidaemia due to isotretinoin and etretinate: possible mechanisms and consequences. Br J Dermatol 1986, 114:401-407.
147. Shalita A.R. Lipid and teratogenic effects of retinoids. J Am Acad Dermatol 1988, 19:197-198.
148. Barth J.H., Macdonald-Hull S.P., Mark J. Isotretinoin therapy for acne vulgaris: a reevaluation of the need for measurements of plasma lipids and liver function tests. Br J Dermatol 1993, 129:704-707.
149. Alcalay J., Landau M., Zucker A. Analysis of laboratory data in acne patients treated with isotretinoin: is there really a need to perform routine laboratory tests?. J Dermatolog Treat 2001, 12:9-12.
150. Stein R.H., Lebwohl M. Acne Therapy: Clincal pearls. Semin Cutan Med Surg 2001, 20:184-189.
151. Lestringant G.G., Frossard P.M., Agarwal M., et al. Variations in lipid and lipoprotein levels during isotretinoin treatment for acne vulgaris with special emphasis on HDL-cholesterol. Int J Dermatol 1997, 36:859-862.
152. Melnik B.C., Bros U., Plewig G. Evaluation of the atherogenic risk of isotretinoin-induced and etretinate-induced alterations of lipoprotein cholesterol metabolism. J Invest Dermatol 1987, 88:39S-43S.
153. Jancin B. With Isotretinoin, triglyceride level may predict risks. Skin Allergy News 2003, 21.
154. Rodondi N., Darioli R., Ramelet A.A., et al. High Risk for Hyperlipidemia and the Metabolic Syndrome after an Episode of Hypertriglyceridemia during 13-cis Retinoic Acid Therapy for Acne: A Pharmacogenetic Study. Ann Intern Med 2002, 136:582-589.
155. McCarter T.L., Chen Y.K. Marked hyperlipidemia and pancreatitis associated with isotretinoin therapy. Am J Gastroenterol 1992, 87:1855-1858.
156. Greene J.P. An adolescent with abdominal pain taking isotretinoin for severe acne. South Med J 2006, 99:992-994.
157. Jamshidi M., Obermeyer R.J., Govindaraj S., et al. Acute Pancreatitis Secondary to Isotretinoin-induced Hyperlipidemia. J Okla State Med Assoc 2002, 95:79-80.
158. Fallon M.B., Boyer J.L. Hepatic toxicity of vitamin A and synthetic retinoids. J Gastroenterol Hepatol 1990, 5:334-342.
159. van Ditzhuijsen T.J., van Haelst U.J., van Dooren-Greebe R.J., et al. Severe hepatotoxic reaction with progression to cirrhosis after use of a novel retinoid (acitretin). J Hepatol 1990, 11:185-188.
160. Roenigk H.H. Liver toxicity of retinoid therapy. J Am Acad Dermatol 1988, 19:19-208.
161. Wang J.I., Jackson T.L., Kaplan D.L. Isotretinoin-associated normalization of hyperbilirubinemia in patients with Gilbert's syndrome. J Am Acad Dermatol 1995, 32:136-138.
162. Pavese P., Kuentz F., Belleville C., et al. Renal impairment induced by isotretinoin. Nephrol Dial Transplant 1997, 12:1299.
163. Fiallo P. Reduced therapeutic activity of Warfarin during treatment with oral isotretinoin. Br J Derm 2004, 150:164.
164. Friedman D.I. Medication-induced intracranial hypertension in dermatology. Am J Clin Dermatol 2005, 6:29-37.
165. Hendrix C.W., Jackson K.A., Whitmore E., et al. The effect of isotretinoin on the pharmacokinetics and pharmacodynamics of ethinyl estradiol and norethindrone. Clin Pharmacol Ther 2004, 75:464-475.
166. Duenward M. Debate on acne drug's safety persists over two decades. NY Times 2002, January 22.
167. Vedantam S. Plane crash revivies Accutane questions: Pilot had prescription for acne medication linked to depression 2002, A02. Washington Post, January 11.